GSK's Nucala application for COPD accepted for review in China

Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally

Senores Pharmaceuticals acquires ANDA for Roflumilast 250 mcg and 500 mcg tablets

AstraZeneca Pharma Pharma India to launch Breztri Aerosphere in Jan 2025

Sanofi’s dupixent approved in the US as the first-ever biologic medicine for patients with COPD

Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype

Strides receive USFDA approval for Theophylline ER tablets, 300 mg and 450 mg

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug

GSK’s RSV vaccine ‘Arexvy’ receives positive European Medicines Agency’s CHMP opinion for adults aged 50-59

Decision on EU marketing authorisation for this population expected by September 2024

USFDA approves expanded age indication for GSK’s RSV vaccine ‘Arexvy’

Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes

Zydus receives final approval from USFDA for Theophylline ER Tablets

Theophylline is used to treat asthma and chronic obstructive pulmonary disease

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024

New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD

Pfizer announces positive results from Phase 3 Study of Abrysvo

ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.